TAVI in Bicuspid Aortic Valve Stenosis: Cautiously Feasible by Manolis, Antonis S
40 
 
EDITORIAL    
TAVI in Bicuspid Aortic Valve Stenosis: 
Cautiously Feasible  
Antonis S. Manolis, MD  
Third Department of Cardiology, Athens University 
School of Medicine, Athens, Greece/E-mail: asm@otenet.gr  
Abstract 
Bicuspid aortic valve (BAV) disease is the most common 
congenital cardiac malformation with a prevalence of 0.4% to 
2%. For a long time, a BAV has not been considered an 
indication for transcatheter aortic valve implantation (TAVI) due 
to insufficient technology and poor procedural results conferred 
by a challenging valvular anatomy leading to poor stability of 
the prosthetic valve and/or paravalvular regurgitation due to 
distorted native valve leaflets. Large randomized controlled 
TAVI trials typically excluded bicuspid aortic stenosis (AS) 
because of its unique anatomic features. However, current 
technological advancements are apparently changing this 
landscape, and over the last few years, TAVI appears technically 
feasible, albeit a demanding procedure, and has been used to 
treat severe bicuspid AoV stenosis with promising results, as 
shown, apart from earlier case reports and patient series, in 
several recent observational studies and comparative trials 
between patients with tricuspid and patients with BAV. Thus, 
current literature cautiously supports a role of TAVI in selected 
BAV AS patients; however, the final role of this technique in 
this challenging group of patients will need to be determined 
from randomized controlled trials comparing TAVI with 
surgical replacement and studies comparing TAVI in bicuspid 
and tricuspid aortic valves. Technological advancements appear 
to play a significant and crucial role in rendering the 
transcatheter approach feasible, efficacious and safe. Rhythmos 
2017;12(3): 40-44.   
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Introduction 
Bicuspid aortic valve (BAV) disease is the most 
common congenital cardiac malformation with a 3:1 male 
predominance.1, 2 A prevalence of BAV of 0.4% to 2% has 
been reported in both the Western and Asian population.3, 
4 A high rate of complications by various degree of aortic 
valve stenosis or aortic valve regurgitation has been 
observed in BAV patients.4-6 There is also a low, albeit 
much higher than in tricuspid aortic valve, incidence of 
infective endocarditis and aortic dissection in this patient 
group.7, 8 Some consider the underlying pathology leading 
to ascending aortic aneurysmal dilation in the context of 
BAV-associated aortopathy.8, 9 BAV has also been 
associated with a higher incidence of intracranial 
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aneurysms.10 There appears to be familial clustering of 
BAV suggestive of genetic linkage, and international 
guidelines advocate that in affected families first-degree 
relatives of patients with BAV be screened.11 Despite a 
male predominance among patients with BAV, 
presentation may be different in the two genders.12 Men 
with BAV may have more frequently moderate/severe 
aortic regurgitation at first presentation compared with 
women, whereas women present more often with 
moderate/severe aortic stenosis compared with men. 
Furthermore, men appear to have more frequent 
endocarditis and aortopathy with aortic dissections than 
women. 
For a long time, a bicuspid aortic valve (BAV) has not 
been considered an indication for transcatheter aortic valve 
implantation (TAVI) due to insufficient technology and 
poor procedural results conferred by this specific and 
challenging valvular anatomy leading to poor stability of 
the prosthetic valve and/or paravalvular regurgitation due 
to distorted native valve leaflets.13 Nevertheless, TAVI has 
been used to treat severe bicuspid aortic stenosis (AS), 
mainly in case reports and small patient series,14 as the 
large randomized controlled trials typically excluded 
bicuspid AS because of its unique anatomic features.  
However, current technological advancements may be 
changing this landscape.15, 16 Patients with BAV have more 
challenging anatomy with altered aortic geometry, larger 
aortic annuli dimensions, more calcified, bulky and 
irregular valve leaflets compared with patients with 
tricuspid aortic valve. Improvements in mechanical 
controlled expansion may be able to reduce the risk of 
elliptical deployment and/ or malpositioning of the 
prosthetic valve. An adaptive seal may reduce paravalvular 
leak. Preliminary data with use of the newer generation 
valves show promising results of TAVI in patients with 
bicuspid anatomies.17, 18 Comparative data between 
patients with tricuspid and patients with BAV undergoing 
TAVI appear promising with equivalent success and 
complication rates.19 Thus, current preliminary data 
suggest that BAV may not be deemed a contraindication 
for TAVI any longer;14, 16, 20-22 however, further studies will 
be needed to confirm the results of these initial reports and 
to support the performance of TAVI in BAV stenosis.  
BAV Morphology Classification 
The most commonly used classification of BAV 
morphology was proposed by Sievers and Schmidtke,23 
depending on number of raphes, spatial position of cusps 
or raphes, and functional status of the valve, with three 
major types identified: type 0 (no raphe), type 1 (one 
raphe), and type 2 (two raphes), followed by two 
supplementary characteristics, spatial position and 
function. A bicuspid aortic valve with one raphe (type 1) 
appears to be the most common type, with the raphe 
usually positioned between the left (L) and right (R) 
coronary sinuses (type 1, L/R), frequently associated with 
a hemodynamic predominant stenosis (S) (type 1, L/R, S). 
Very few patients had a “purely” bicuspid aortic valve with 
no raphe (type 0). In another study, the presence of a raphe 
was associated with a higher prevalence of significant 
aortic stenosis and regurgitation. 24  
In another similar, possibly more practical 
classification, again three BAV morphologies appear to 
predominate.25 A tricommissural BAV, with 1 
commissure completely fused between 2 cusps, often 
referred to as “functional” or “acquired” BAV; in this 
morphology, fusion is not seen in the basal third of the 
sinus and occurs at or close to the commissural level. A 
bicommissural raphe type has 2 cusps fused by a fibrous 
or calcified ridge of various heights, does not reach the 
height of the commissure; in this morphology, fusion of 
cusps occurs at or proximal to the basal third of the sinus, 
and the raphe may also vary in terms of calcification and 
vertical height. In the bicommissural non-raphe type, 2 
cusps are completely fused from their basal origin but there 
is no visible seam; in this morphology, there are only 2 
commissures with no raphe or third commissure.   
Studies of TAVI in patients with BAV 
 A preliminary systematic review of 4 case series with 
86 patients and 6 case reports reported relatively favorable 
results of TAVI in BAV patients with initially successful 
procedure attained in all but one patient, however there 
was an 8.6% 30-day mortality and a considerable 
complication rate with 21% requiring a pacemaker, 14% 
experiencing major bleeding and 23.6% vascular access 
complications.20 Paravalvular regurgitation was observed 
in 68.5% of patients, however the majority (80%) was 
reported as only mild. A subsequent analysis of short and 
mid-term pooled data from 7 observational studies 
comparing 149 BAV and 2096 non-BAV patients 
undergoing TAVI suggested that TAVI is feasible and safe 
in older patients with BAV.26 Between the BAV and non-
BAV cohorts, there was no difference in 30-day mortality 
(8.3% vs 9%), post-TAVI mean peak gradients (weighted 
mean difference, 0.36 mmHg), moderate or severe 
paravalvular leak (25.7% vs 19.9%), pacemaker 
implantations (18.5% vs 27.9%), life-threatening bleeding 
(8.2% vs 13.9%), major bleeding (20% vs 16.8%), 
conversion to conventional surgery (1.9% vs 1.2%) and 
vascular complications (8.6% vs 10.1%) (all P=NS).  
 In a retrospective multicenter analysis of 139 patients 
(mean age 78+8.9 years; STS score 4.9+3.4%) undergoing 
TAVI with the balloon-expandable (n = 48) or self-
expandable valve (n = 91) systems for BAV stenosis 
(65.5%), regurgitation (0.7%), or mixed disease (33.8%), 
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procedural mortality was 3.6%, with valve embolization in 
2.2% and conversion to surgery in 2.2%.27 The mean aortic 
gradient decreased from 48.7+16.5mmHg to 
11.4+9.9mmHg (p <0.0001). Post-implantation aortic 
regurgitation (AR) grade >2 occurred in 28.4% (19.6% 
balloon-expandable vs. 32.2% self-expandable valve, p = 
0.11) but was prevalent in only 17.4% when CT-based 
valve sizing was performed (16.7% balloon-expandable 
valve vs. 17.6% self-expandable valve, p = 0.99). Thirty-
day device safety, success, and efficacy were noted in 
79.1%, 89.9%, and 84.9% of patients, respectively. One-
year mortality was 17.5%. Major vascular complications 
were associated with increased 1-year mortality (OR: 5.66; 
p = 0.03). The authors concluded that TAVI in BAV is 
feasible with encouraging short- and intermediate-term 
clinical outcomes. Importantly, a high incidence of post-
implantation AR is observed, which appears to be 
mitigated by CT-based valve sizing. 
According to an international patient level multicenter 
analysis on outcomes in 108 patients with BAV 
undergoing TAVI, the primary outcome (a composite of 
30-day mortality, stroke, life-threatening bleeding, acute 
kidney injury, coronary artery obstruction, major vascular 
complication and valve related dysfunction) occurred in 
~27% of patients, mainly driven by re-intervention for 
valve malposition (9.3%).22  The 30-day and 1-year 
mortality rates were 8.3% and 16.9% respectively; with 
severe paravalvular regurgitation occurring in 9.6% of 
patients. Device success was achieved in 85.2% of cases 
with pacemaker insertion in 19.4%. The authors concluded 
that in selected patients with BAV and severe AS, TAVI 
appears both safe and feasible with acceptable clinical 
outcomes.  
According to a systematic literature review of 8 case 
reports and 4 case series and meta-analysis of 5 case-
control/cohort studies comprising 166 BAV patients, 
device success rate achieved for TAVI in this cohort of 
BAV patients was 95.2%.28  The 30-day mortality rate was 
8.4%, and the medium-term (range from 6 months to 2 
years) mortality rate reported was 17.9%. Overall, the 
performance of TAVI in BAV patients was comparable to 
that in non-BAV patients (30-day mortality rate relative 
risk - RR 1.05, p = 0.87; device success rate RR = 1.00, p 
= 0.94; incidence of moderate to severe paravalvular 
regurgitation: RR = 1.25, p = 0.25). The authors concluded 
that TAVI may be feasible and safe for treating BAV 
stenosis patients. Other observational and comparative 
studies have also reported similar efficacy of TAVI in 
patients with bicuspid or tricuspid aortic valve anatomy 
with sustained and acceptable mid-term prosthesis 
hemodynamic performance.18 Newer generation 
prostheses appear to confer more favorable valve 
performance.29  Nevertheless, particularly challenging are 
anatomies with a large aortic annulus, whereby TAVI is 
rarely performed due to the risk of residual paravalvular 
aortic leakage.30  
In a multicenter study analyzing imaging with pre-
procedural computed tomography (CT), TAVI achieved 
favorable outcomes in 130 patients with bicuspid aortic 
valve (BAV) stenosis, albeit with high permanent 
pacemaker rates.25 Specifically, bicommissural BAV (vs 
tricommissural) accounted for ~69-96% of patients. For 
bicommissural bicuspids, non-raphe type (vs raphe type) 
BAV accounted for 9-62%. Overall rate of 30-day 
mortality was 3.8% and of cerebrovascular events 3.2%. 
The rate of new permanent pacemaker insertion was high 
(26.2%) and similar between balloon-expandable and self-
expanding valves (25.5% vs 26.9%). Paravalvular aortic 
regurgitation (PAR) ≥ moderate was 18.1% overall but 
lower at 11.5% in those with pre-procedural CT. In the 
absence of pre-procedural CT, there was an excess of PAR. 
Predictors of PAR included intercommissural distance for 
bicommissural bicuspids (odd ratio -OR 1.37; p = 0.036) 
and lack of a baseline CT for annular measurement (OR 
3.03; p = 0.018).  
 TAVI in bicuspid AS appears to be associated with 
lower device success rate, particularly with the early-
generation devices. According to a propensity score 
matching comparison between 546 pairs of bicuspid and 
tricuspid AS undergoing TAVI derived from a multicenter 
registry, patients with bicuspid AS had more frequent 
conversion to surgery (2% vs 0.2%; p = 0.006) and a 
significantly lower device success rate (85.3% vs. 91.4%; 
p = 0.002).31 Within the group receiving early-generation 
devices, bicuspid AS had more frequent aortic root injury 
(4.5% vs 0%; p = 0.015) when receiving the balloon-
expanding device, and moderate-to-severe paravalvular 
leak (19.4% vs. 10.5%; p = 0.02) when receiving the self-
expanding device. Among patients with new-generation 
devices, however, procedural results were comparable 
across different prostheses. The cumulative all-cause 
mortality rates at 2 years were comparable between 
bicuspid and tricuspid AS (17.2% vs 19.4%; p = 0.28).  
Paravalvular Regurgitation 
In BAV patients undergoing TAVI, increased rates of 
paravalvular leak (particularly in the absence of baseline 
contrast CT scan) and permanent pacemaker implantation 
have been observed regardless of device design and leaflet 
morphology.25  However, newer-generation valve devices 
have shown more promising results in mitigating these 
high rates of paravalvular aortic regurgitation.16, 29, 30    
Pacemaker Implantation 
Higher rates of pacemaker implantation after TAVI in 
bicuspid AS do require further investigation. Pacemaker 
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implantation rates reported during TAVI of BAV patients 
range from 14% to 50%, and are even higher than the 
generally high rates observed with self-expandable devices 
in patients with tricuspid aortic valve stenosis.29 
Unfortunately, newer generation devices have not 
curtailed these rates. 31 Perhaps, avoiding low implantation 
positions may play a role.16   
Technical Challenges   
Close preoperative and intraoperative analyses of 
the aortic valve anatomy are mandatory for successful 
TAVI in BAV cases.32  Preprocedural multidetector 
computed tomographic (CT) imaging for detailed 
measurements of the aortic annulus annulus, ascending 
aorta diameter, coronary ostia height, sinus area, sino-
tubular junction area, calcification and eccentricity index 
are all required in order to determine whether currently 
available valved stents may be able to fit the specific 
anatomy.33   
Type I BAV anatomy with left and right cusp fusion 
appears to have significantly better outcomes than other 
valve variants.22   
Conclusion  
In patients with bicuspid AS, the altered valve 
anatomy with the elliptic shape of the BAV annulus, 
combined with the asymmetric heavy calcifications of the 
leaflets pose technical challenges for TAVI. Nevertheless, 
TAVI appears technically feasible, albeit a demanding 
procedure, and current literature cautiously supports a role 
of TAVI in selected BAV AS patients; however, the final 
role of this technique in this challenging group of patients 
will need to be determined from randomized controlled 
trials comparing TAVI with surgical replacement and 
studies comparing TAVI in bicuspid and tricuspid aortic 
valves. Technological advancements appear to play a 
significant and crucial role in rendering the transcatheter 
approach feasible, efficacious and safe.   
Table 1. Parameters determining a successful TAVI 
procedure in patients with symptomatic severe BAV 
stenosis  
● Pre-procedural imaging (CT-based sizing) 
CT is the preferred modality for morphology 
delineation, calcium characterization, and quantification 
and can also optimally assess for aortopathy / CT annular 
sizing helps to select an appropriately sized implant  
● Type of prosthetic valve 
A newer generation low profile valve is preferable with 
improved sealing properties of the external sealing layer of 
the inflow portion  
Devices moderately oversized (e.g. ~10% of the 
annular area) may have a low rate of AR   
● Procedure 
Improved accuracy of valve positioning with an 
improved valve delivery system 
Increased operator experience and case planning   
● Caveats 
Cautious with valve oversizing for fear of annular 
rupture/should be guided by CT annular measurements   
Beware of asymmetric expansion of some valves  
Self-expanding valves might be more capable of 
conforming to the irregular orifice of the bicuspid valve 
but less capable of achieving a circular formation after 
implantation /  
However, there is no conclusive evidence for an 
advantage of a certain type of valve in preventing AR or 
improving clinical outcomes  
Possible higher device success rate and lower incidence 
of significant AR in patients with type 1L-R bicuspid 
valves (fusion of the left and right cusps)  
Still high pacemaker implantation rates, with either 
balloon- or self-expandable valves, ranging from 14% to 
50% / maybe associated with low implantation positions  
__________________________________________ 
AR = aortic regurgitation; BAV = bicuspid aortic valve; CT = 
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